Table 3

Correlations between parameters of systolic and diastolic function and disease variables in 59 patients with JDM during disease course, at follow-up and 1 year postdiagnosis

	Long axis-strain		EF		e′
	r_sp	p Value	r_sp	p Value	r_sp	p Value
During disease course
Prednisolone cum	−0.07	0.59	0.17	0.21	−0.40	0.002
Methotrexate	0.19	0.15	−0.11	0.45	0.00	0.99
Smoking daily	−0.11	0.46	−0.04	0.80	−0.15	0.30
Follow-up
BP systolic	−0.53	<0.001	0.13	0.36	−0.47	<0.001
BP diastolic	−0.46	<0.001	0.23	0.10	−0.57	<0.001
Smoking daily	−0.16	0.23	−0.06	0.66	−0.13	0.35
MDI total	−0.33	0.012	0.05	0.72	−0.60	<0.001
DAS total	−0.13	0.32	−0.02	0.88	−0.14	0.28
SF 36 PCS*	0.05	0.65	−0.10	0.35	0.20	0.05
CHAQ/HAQ	0.05	0.73	0.14	0.31	−0.08	0.53
1 year postdiagnosis
MDI total	−0.36	0.006	−0.12	0.40	−0.46	<0.001
DAS total	−0.40	0.002	0.28	0.043	−0.63	<0.001
DAS skin	−0.41	0.001	0.30	0.029	−0.62	<0.001
DAS muscle	−0.21	0.11	0.21	0.13	−0.46	<0.001

Values are r_sp (Spearman correlation coefficient) or p Value.
BP, blood pressure; CHAQ/HAQ, (Child) Health Assessment Questionnaire; DAS, Disease Activity Score; e′, early diastolic tissue velocity; EF, left ventricular ejection fraction; JDM, juvenile dermatomyositis; long-axis strain, mitral annulus displacement as percentage of end-diastolic left ventricular length; Prednisolone cum, cumulative prednisolone dose during disease course; Methotrexate, use during disease course; MDI, Myositis Damage Index; SF-36 PCS, Short Form-36 physical component summary (*only validated in patients 14 years or older, n=48).